About Souzhou Ribo Life Science
Souzhou Ribo Life Science is a company based in Suzhou (China) founded in 2007 by Zicai Liang. Souzhou Ribo Life Science has raised $200.79 million across 6 funding rounds from investors including CICC, Panlin Capital and Sany Innovation Fund. Souzhou Ribo Life Science operates in a competitive market with competitors including Jazz Pharmaceuticals, Horizon Discovery, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter Suzhou, China
- Founders Zicai Liang
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Suzhou Ribo Life Science Co., Ltd. Class H
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$200.79 M (USD)
in 6 rounds
-
Latest Funding Round
$40 M (USD), Series E
Jul 29, 2022
-
Investors
CICC
& 14 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Souzhou Ribo Life Science
Souzhou Ribo Life Science is a publicly listed company on the HKEX with ticker symbol 6938 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Souzhou Ribo Life Science
Souzhou Ribo Life Science has successfully raised a total of $200.79M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $40 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Souzhou Ribo Life Science
Souzhou Ribo Life Science has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include CICC, Panlin Capital and Sany Innovation Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital investments are provided to high-tech enterprises.
|
Locked | Locked | Locked | |
|
Private equity & venture capital firm
|
Locked | Locked | Locked |
Investor details for Souzhou Ribo Life Science
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Souzhou Ribo Life Science
Investment portfolio details for Souzhou Ribo Life Science
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Souzhou Ribo Life Science
Detailed financials for Souzhou Ribo Life Science
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Souzhou Ribo Life Science Comparisons
Peer comparison for Souzhou Ribo Life Science
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Souzhou Ribo Life Science
Souzhou Ribo Life Science operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Horizon Discovery, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Genetically modified cell lines are developed using AAV gene-editing platform.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of Souzhou Ribo Life Science
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Souzhou Ribo Life Science
Complete news archive for Souzhou Ribo Life Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Souzhou Ribo Life Science
Souzhou Ribo Life Science was founded in 2007 and raised its 1st funding round 7 years after it was founded.
Souzhou Ribo Life Science is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Souzhou Ribo Life Science is a funded company, having raised a total of $200.79M across 6 funding rounds to date.
Founded in 2007 and based in Suzhou, China, the company operates in the biotechnology sector, specializing in nucleic acid drugs through RNA interference (RNAi) technology. Focus areas include drug discovery, siRNA design and screening, chemical modifications, delivery systems, pharmacokinetic studies, safety evaluations, and clinical trials. Therapeutics targeting Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, and HIV are also provided.
Souzhou Ribo Life Science's top competitors include Jazz Pharmaceuticals, Horizon Discovery and C4 Therapeutics.
Yes, Souzhou Ribo Life Science is publicly traded on HKEX under the ticker symbol 6938.
Souzhou Ribo Life Science has 15 investors. Key investors include CICC, Panlin Capital, Sany Innovation Fund, Langmafeng Venture Capital, and Free Trade Zone Fund.
The ticker symbol of Souzhou Ribo Life Science is 6938 on HKEX.